Glenmark Pharma has reported a rise of 23.5% (YoY) in its first quarter net profit. Its consolidated net profit increased to Rs 210 crore against Rs 170 crore in the corresponding quarter last fiscal year.
In an interview with CNBC-TV18, Surajit Pal, pharma analyst, Elara Capital said, the top-line is very much in line, just 3% below his expectations.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
